-
-
-
-
-
-
-
Bragar Eagel & Squire, P.C. Is Investigating Reata, Comerica, and DZS and Encourages Investors to Contact the Firm
-
-
-
-
-
-
-
Reata Pharmaceuticals, Inc. Announces Third Quarter 2022 Financial Results and Provides an Update on Clinical Development Programs
-
-
-
-
-
-
-
Reata Pharmaceuticals, Inc. Announces First Quarter 2022 Financial Results and Provides an Update on Clinical Development Programs
-
-
-
-
-
-
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Robinhood, Reata Pharmaceuticals, Desktop Metal, and Chegg and Encourages Investors to Contact the Firm
-
-
-
-
-
-
-
Reata Pharma (RETA) Tops Q1 EPS by 94c
-
-
-
-
-
-
-
Pre-Open Movers 12/02: (TG) (IBIO) (AIV) Higher; (OVID) (IRTC) (WKHS) Lower (more...)
-
-
-
-
-
-
-
Reata Announces Positive Results From Year 2 of the Pivotal Phase 3 CARDINAL Study of Bardoxolone Methyl in Patients with Alport Syndrome
-
1,197,548 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

